gdc
FDA NewsLymphomaNewsworthy

Calquence Newest Treatment Approved for Mantle-Cell Lymphoma

In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.

December 2017 Vol 3 No 6 – December 18, 2017

On October 31, 2017, the FDA accelerated the approval of Calquence (acalabrutinib; from AstraZeneca) for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy. Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma.

“Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies.”

This approval was based on a clinical trial of patients with mantle-cell lymphoma that showed that 81% of patients who received Calquence had a complete or partial response to this drug. Serious side effects with Calquence include bleeding, infections, and irregular heartbeat. Women who breastfeed should not take this drug. In addition, new cases of cancer occurred in some patients who used Calquence.

Recommended For You
LymphomaPatient Stories
Never Say Never: How I Beat the Odds
By Sydney Figone
After achieving remission of stage IV Hodgkin lymphoma, Sydney was told she would have less than a 5% chance of conception because of the treatment she received. Then 2 miracles happened.
Breast CancerNewsworthy
Living Beyond Breast Cancer to Host 12th Annual National Metastatic Breast Cancer Conference in Philadelphia, April 20-22
Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.
Breast CancerNewsworthyWeb Exclusives
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
LeukemiaLymphomaNewsworthy
Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers
The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
Last modified: January 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Need multiple copies? Click here